Physician profile
Clint D Simpson
NPI 1053553719
$3,606.09
in general payments reported to CMS, 2019-2025
23 companies · $651 in 2025
The $651 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $161 · 2020: $165 · 2021: $789 · 2022: $464 · 2023: $694 · 2024: $682 · 2025: $651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,009 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,009.17 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,097.13 | 2019-2025 | Hydrus Microstent, Clareon, Rocklatan |
| Ivantis, INC | $557.01 | 2021 | |
| Allergan, INC. | $262.59 | 2020-2022 | |
| Abbvie INC. | $250.50 | 2022-2025 | Xen Glaucoma Treatment System, Durysta |
| Tarsus Pharmaceuticals, INC. | $185.39 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $184.81 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $151.50 | 2022-2025 | Envista Mx60 Iol, Miebo, Vyzulta |
| Sight Sciences, INC. | $140.32 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $136.85 | 2019-2021 | |
| New World Medical,INC. | $129.92 | 2021-2025 | Ahmed Glaucoma Valve, Via360, Clearpath |
| Biotissue Holdings INC. | $83.58 | 2023-2025 | |
| Oyster Point Pharma, INC. | $74.81 | 2022-2024 | Tyrvaya, Ryzumvi |
| Johnson & Johnson Surgical Vision, INC. | $69.42 | 2024-2025 | Tecnis Iol |
| Sun Pharmaceutical Industries INC. | $51.94 | 2019-2024 | |
| Glaukos Corporation | $42.35 | 2021-2024 | Istent Trabecular Micro-Bypass System Model Is3, Idose |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $41.94 | 2023 | Tepezza |
| Dompe US, INC. | $35.48 | 2022-2024 | Oxervate |
| Thea Pharma INC. | $24.58 | 2024 | Iyuzeh |
| Beaver-Visitec International, INC. | $20.99 | 2021 | |
| Ocular Therapeutix, INC. | $19.81 | 2023 | Dextenza |
| Apellis Pharmaceuticals, INC. | $15.48 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $15.27 | 2022 | |
| Mallinckrodt Hospital Products INC. | $14.42 | 2024 | Acthar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clint Simpson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.